China's National Medical Products Administration accepted Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) drug marketing authorization application for HRG2010 capsules, according to a Shanghai bourse filing on Tuesday.
The drug is used for the treatment of Parkinson's disease.